Phaseline

Companies › Elpiscience (Suzhou) Biopharma

Elpiscience (Suzhou) Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ES014–Phase 2Desmoid Tumor; Solid TumorFeb 2027
ES102–Phase 2Non-Small Cell Lung CancerFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05717348ES014Phase 1Solid TumorOncologyFeb 2027
NCT06623136ES102Phase 2Non-Small Cell Lung CancerOncologyFeb 2027
NCT07541430ES014Phase 2Desmoid TumorOncologyJan 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

EpicentRx Ryvu Therapeutics Criterium Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Inhibrx Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.